New Delhi : Drug firm Zydus Cadila today launched biosimilar of Adalimumab, used for treatment of auto immune disorders, at a price much lower than the innovator drug in India. Developed by Zydus Research Centre, the biosimilar has been approved by the Drug Controller General of India and will be marketed under the brand name ‘Exemptia’ at a cost that will be one-fifth of the innovator product Humira by AbbVie.
When asked about the global sales of Adalimumab, Zydus Cadila Deputy Managing Director Sharvil P Patel told PTI that, “the sales were around USD 12 billion worldwide.”
